報價延遲最少15分鐘:2025/09/04 04:00 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.91
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.57/-2.89
|
|
企業價值
142.57M
|
| 資產負債 |
|
每股賬面淨值
0.74
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
148.34M
|
|
每股收益
1.89
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/04 04:00 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. |
